Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTXBiotechnology
+$0.10 today
- Market cap
- $980.14M
- Beta
- 0.00
Volume 0.68M
Average 0.41M
SPTX Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Net Change in Cash history
Currency unavailable · from the cash flow
No Net Change in Cash data reported for this period type.
Net Change in Cash vs competitors
How SPTX compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $300.86M USD | — | +123.5% | — |
| LTM Mar 2026 | $57.76M USD | +332.3% | — | 26.5% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $20.45M USD | +222.7% | — | 102.3% |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $19M USD | +133.9% | — | — |
| LTM Mar 2026 | $5.55M USD | +104.3% | -32.6% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $2.31M USD | -137.3% | +285.2% | — |
| LTM Mar 2026 | $2.3M USD | -101.4% | — | — | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding SPTX) | — | +119.1% | +123.5% | 64.4% | |
Competitors are the stored peer set for SPTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Seaport Therapeutics, Inc. Common Stock
NASDAQ:SPTX
Intrinsic Alpha fair value
Locked
Current Price
$18.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.